APA (7th ed.) Citation

Gu, X., Zhong, Y., & Huang, H. (2024). Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review. Frontiers in pharmacology, 15, 1410684. https://doi.org/10.3389/fphar.2024.1410684

Chicago Style (17th ed.) Citation

Gu, Xiaofei, Yonghong Zhong, and Huaqiong Huang. "Case Report: EGFR-TKI Rechallenge After Osimertinib-induced Interstitial Lung Disease: A Case Report and Literature Review." Frontiers in Pharmacology 15 (2024): 1410684. https://doi.org/10.3389/fphar.2024.1410684.

MLA (9th ed.) Citation

Gu, Xiaofei, et al. "Case Report: EGFR-TKI Rechallenge After Osimertinib-induced Interstitial Lung Disease: A Case Report and Literature Review." Frontiers in Pharmacology, vol. 15, 2024, p. 1410684, https://doi.org/10.3389/fphar.2024.1410684.